Brainsway, having won FDA clearance at the beginning of the year for its Deep TMS (transcranial magnetic stimulation) system as a treatment option for drug resistant major depressive disorder, is about to begin shipments of its device in the U.S. Deep TMS sets ups highly focused magnetic fields within a special helmet to target specific regions of the brain. In Europe, besides depression treatment, the system is also approved for addressing neuropathic chronic pain, bi-polar disorder, and schizophrenia and is being investigated for conditions such as Parkinson’s, PTSD, and as an aid in quitting smoking.
Discover The World's MOST COMPREHENSIVE Mental Health Assessment Platform
Efficiently assess your patients for 80+ possible conditions with a single dynamic, intuitive mental health assessment. As low as $12 per patient per year.
Treatment is conducted in an outpatient setting during 20-minute sessions over a four week period. Moreover, no sedation is required during treatment sessions and clinical trials haven’t detected any significant long term side effects.